aluates Reports

$ 0.0

Automative

Global Oncology Drugs Market Research Report 2026

Published Date: 2026-03-03

Report Code: QYRE-Auto-4R430

Global Oncology Drugs Market Size Status and Forecast 2021 2027

BUY CHAPTERS

Global Oncology Drugs Market Research Report 2026

Code: QYRE-Auto-4R430

Report

2026-03-03

Pages:159

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Roche

Astrazeneca plc

Sanofi

Novartis

Celgene

Bristol–Myers Squibb

Johnson & Johnson

Merck

Pfizer Inc

Amgen Inc

Eli Lilly

AbbVie

Takeda

Astellas

Ipsen S A

Bayer

Biogen Idec

TEVA

Otsuka

Eisai Co Ltd

Merck KGaA

Gilead Sciences

Hengrui Medicine

Oncology Drugs Market Size

The global Oncology Drugs market was valued at US$ 262090 million in 2025 and is anticipated to reach US$ 484260 million by 2032, at a CAGR of 9.3% from 2026 to 2032.

Oncology Drugs Market

Oncology drugs are pharmaceutical agents used to prevent, treat, or manage various types of cancer. This category includes chemotherapy, targeted therapies, immunotherapies, hormone therapies, and emerging treatments such as cell-based therapies like CAR-T. These drugs function through different mechanisms, such as inhibiting cancer cell growth, inducing apoptosis, blocking angiogenesis, or enhancing the immune system’s ability to recognize and destroy malignant cells. Oncology drugs play a critical role in modern medicine and represent one of the most dynamic and innovative sectors in the pharmaceutical industry.

The oncology drugs market is experiencing robust growth driven by the increasing global burden of cancer and rising awareness of early diagnosis and treatment. Aging populations, lifestyle-related risk factors such as smoking, poor diet, and lack of physical activity, along with environmental exposures, have all contributed to higher cancer incidence rates. Technological advancements in molecular biology and genomics have accelerated the development of targeted therapies, immunotherapies, and personalized medicine, which offer improved efficacy with fewer side effects. Governments and health organizations worldwide are increasing investments in cancer research, diagnostics, and treatment infrastructure, further supporting market expansion. Additionally, the growing adoption of biosimilars and the introduction of new drug classes like CAR-T cell therapies and checkpoint inhibitors are enhancing treatment options and accessibility for patients across various cancer types.

Despite significant progress, the oncology drugs market faces notable challenges. One of the key issues is the high cost of cancer drugs, particularly biologics and targeted therapies, which poses a financial burden on healthcare systems and patients, especially in low- and middle-income countries. Drug development in oncology is highly complex, expensive, and time-consuming, with a high failure rate during clinical trials. Regulatory hurdles, including long approval timelines and stringent safety requirements, can delay the introduction of innovative therapies. Moreover, the emergence of drug resistance in certain cancers, such as melanoma or non-small cell lung cancer, limits the long-term effectiveness of current treatments. Inequitable access to oncology care, due to disparities in healthcare infrastructure, insurance coverage, and geographical availability, further restricts market reach and poses a major public health concern globally.

This report delivers a comprehensive overview of the global Oncology Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Oncology Drugs. The Oncology Drugs market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Oncology Drugs market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Oncology Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Oncology Drugs Market Report

Report Metric	Details
Report Name	Oncology Drugs Market
Accounted market size in 2025	US$ 262090 million
Forecasted market size in 2032	US$ 484260 million
CAGR	9.3%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Chemotherapy Targeted Therapy Immunotherapy (Biologic Therapy) Hormonal Therapy Others
Segment by Application	Blood Cancer Breast Cancer Gastrointestinal Cancer Prostate Cancer Respiratory or Lung Cancer Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, AbbVie, Takeda, Astellas, Ipsen, Sanofi, Bayer, Biogen Idec, Teva, Otsuka, Eisai, Merck KGaA, Gilead Sciences, Hengrui Medicine
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Oncology Drugs companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Oncology Drugs Market growing?

Ans: The Oncology Drugs Market witnessing a CAGR of 9.3% during the forecast period 2026-2032.

What is the Oncology Drugs Market size in 2032?

Ans: The Oncology Drugs Market size in 2032 will be US$ 484260 million.

Who are the main players in the Oncology Drugs Market report?

Ans: The main players in the Oncology Drugs Market are Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, AbbVie, Takeda, Astellas, Ipsen, Sanofi, Bayer, Biogen Idec, Teva, Otsuka, Eisai, Merck KGaA, Gilead Sciences, Hengrui Medicine

What are the Application segmentation covered in the Oncology Drugs Market report?

Ans: The Applications covered in the Oncology Drugs Market report are Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory or Lung Cancer, Others

What are the Type segmentation covered in the Oncology Drugs Market report?

Ans: The Types covered in the Oncology Drugs Market report are Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Oncology Drugs Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Chemotherapy

1.2.3 Targeted Therapy

1.2.4 Immunotherapy (Biologic Therapy)

1.2.5 Hormonal Therapy

1.2.6 Others

1.3 Market by Application

1.3.1 Global Oncology Drugs Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Blood Cancer

1.3.3 Breast Cancer

1.3.4 Gastrointestinal Cancer

1.3.5 Prostate Cancer

1.3.6 Respiratory or Lung Cancer

1.3.7 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Oncology Drugs Market Perspective (2021–2032)

2.2 Global Oncology Drugs Growth Trends by Region

2.2.1 Global Oncology Drugs Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Oncology Drugs Historic Market Size by Region (2021–2026)

2.2.3 Oncology Drugs Forecasted Market Size by Region (2027–2032)

2.3 Oncology Drugs Market Dynamics

2.3.1 Oncology Drugs Industry Trends

2.3.2 Oncology Drugs Market Drivers

2.3.3 Oncology Drugs Market Challenges

2.3.4 Oncology Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Oncology Drugs Players by Revenue

3.1.1 Global Top Oncology Drugs Players by Revenue (2021–2026)

3.1.2 Global Oncology Drugs Revenue Market Share by Players (2021–2026)

3.2 Global Top Oncology Drugs Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Oncology Drugs Revenue

3.4 Global Oncology Drugs Market Concentration Ratio

3.4.1 Global Oncology Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Oncology Drugs Revenue in 2025

3.5 Global Key Players of Oncology Drugs Head Offices and Areas Served

3.6 Global Key Players of Oncology Drugs, Products and Applications

3.7 Global Key Players of Oncology Drugs, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Oncology Drugs Breakdown Data by Type

4.1 Global Oncology Drugs Historic Market Size by Type (2021–2026)

4.2 Global Oncology Drugs Forecasted Market Size by Type (2027–2032)

5 Oncology Drugs Breakdown Data by Application

5.1 Global Oncology Drugs Historic Market Size by Application (2021–2026)

5.2 Global Oncology Drugs Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Oncology Drugs Market Size (2021–2032)

6.2 North America Oncology Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Oncology Drugs Market Size by Country (2021–2026)

6.4 North America Oncology Drugs Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Oncology Drugs Market Size (2021–2032)

7.2 Europe Oncology Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Oncology Drugs Market Size by Country (2021–2026)

7.4 Europe Oncology Drugs Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Oncology Drugs Market Size (2021–2032)

8.2 Asia-Pacific Oncology Drugs Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Oncology Drugs Market Size by Region (2021–2026)

8.4 Asia-Pacific Oncology Drugs Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Oncology Drugs Market Size (2021–2032)

9.2 Latin America Oncology Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Oncology Drugs Market Size by Country (2021–2026)

9.4 Latin America Oncology Drugs Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Oncology Drugs Market Size (2021–2032)

10.2 Middle East & Africa Oncology Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Oncology Drugs Market Size by Country (2021–2026)

10.4 Middle East & Africa Oncology Drugs Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Details

11.1.2 Roche Business Overview

11.1.3 Roche Oncology Drugs Introduction

11.1.4 Roche Revenue in Oncology Drugs Business (2021–2026)

11.1.5 Roche Recent Development

11.2 Celgene

11.2.1 Celgene Company Details

11.2.2 Celgene Business Overview

11.2.3 Celgene Oncology Drugs Introduction

11.2.4 Celgene Revenue in Oncology Drugs Business (2021–2026)

11.2.5 Celgene Recent Development

11.3 Novartis

11.3.1 Novartis Company Details

11.3.2 Novartis Business Overview

11.3.3 Novartis Oncology Drugs Introduction

11.3.4 Novartis Revenue in Oncology Drugs Business (2021–2026)

11.3.5 Novartis Recent Development

11.4 Bristol-Myers Squibb

11.4.1 Bristol-Myers Squibb Company Details

11.4.2 Bristol-Myers Squibb Business Overview

11.4.3 Bristol-Myers Squibb Oncology Drugs Introduction

11.4.4 Bristol-Myers Squibb Revenue in Oncology Drugs Business (2021–2026)

11.4.5 Bristol-Myers Squibb Recent Development

11.5 Johnson & Johnson

11.5.1 Johnson & Johnson Company Details

11.5.2 Johnson & Johnson Business Overview

11.5.3 Johnson & Johnson Oncology Drugs Introduction

11.5.4 Johnson & Johnson Revenue in Oncology Drugs Business (2021–2026)

11.5.5 Johnson & Johnson Recent Development

11.6 Merck & Co.

11.6.1 Merck & Co. Company Details

11.6.2 Merck & Co. Business Overview

11.6.3 Merck & Co. Oncology Drugs Introduction

11.6.4 Merck & Co. Revenue in Oncology Drugs Business (2021–2026)

11.6.5 Merck & Co. Recent Development

11.7 AstraZeneca

11.7.1 AstraZeneca Company Details

11.7.2 AstraZeneca Business Overview

11.7.3 AstraZeneca Oncology Drugs Introduction

11.7.4 AstraZeneca Revenue in Oncology Drugs Business (2021–2026)

11.7.5 AstraZeneca Recent Development

11.8 Pfizer

11.8.1 Pfizer Company Details

11.8.2 Pfizer Business Overview

11.8.3 Pfizer Oncology Drugs Introduction

11.8.4 Pfizer Revenue in Oncology Drugs Business (2021–2026)

11.8.5 Pfizer Recent Development

11.9 Amgen

11.9.1 Amgen Company Details

11.9.2 Amgen Business Overview

11.9.3 Amgen Oncology Drugs Introduction

11.9.4 Amgen Revenue in Oncology Drugs Business (2021–2026)

11.9.5 Amgen Recent Development

11.10 Eli Lilly

11.10.1 Eli Lilly Company Details

11.10.2 Eli Lilly Business Overview

11.10.3 Eli Lilly Oncology Drugs Introduction

11.10.4 Eli Lilly Revenue in Oncology Drugs Business (2021–2026)

11.10.5 Eli Lilly Recent Development

11.11 AbbVie

11.11.1 AbbVie Company Details

11.11.2 AbbVie Business Overview

11.11.3 AbbVie Oncology Drugs Introduction

11.11.4 AbbVie Revenue in Oncology Drugs Business (2021–2026)

11.11.5 AbbVie Recent Development

11.12 Takeda

11.12.1 Takeda Company Details

11.12.2 Takeda Business Overview

11.12.3 Takeda Oncology Drugs Introduction

11.12.4 Takeda Revenue in Oncology Drugs Business (2021–2026)

11.12.5 Takeda Recent Development

11.13 Astellas

11.13.1 Astellas Company Details

11.13.2 Astellas Business Overview

11.13.3 Astellas Oncology Drugs Introduction

11.13.4 Astellas Revenue in Oncology Drugs Business (2021–2026)

11.13.5 Astellas Recent Development

11.14 Ipsen

11.14.1 Ipsen Company Details

11.14.2 Ipsen Business Overview

11.14.3 Ipsen Oncology Drugs Introduction

11.14.4 Ipsen Revenue in Oncology Drugs Business (2021–2026)

11.14.5 Ipsen Recent Development

11.15 Sanofi

11.15.1 Sanofi Company Details

11.15.2 Sanofi Business Overview

11.15.3 Sanofi Oncology Drugs Introduction

11.15.4 Sanofi Revenue in Oncology Drugs Business (2021–2026)

11.15.5 Sanofi Recent Development

11.16 Bayer

11.16.1 Bayer Company Details

11.16.2 Bayer Business Overview

11.16.3 Bayer Oncology Drugs Introduction

11.16.4 Bayer Revenue in Oncology Drugs Business (2021–2026)

11.16.5 Bayer Recent Development

11.17 Biogen Idec

11.17.1 Biogen Idec Company Details

11.17.2 Biogen Idec Business Overview

11.17.3 Biogen Idec Oncology Drugs Introduction

11.17.4 Biogen Idec Revenue in Oncology Drugs Business (2021–2026)

11.17.5 Biogen Idec Recent Development

11.18 Teva

11.18.1 Teva Company Details

11.18.2 Teva Business Overview

11.18.3 Teva Oncology Drugs Introduction

11.18.4 Teva Revenue in Oncology Drugs Business (2021–2026)

11.18.5 Teva Recent Development

11.19 Otsuka

11.19.1 Otsuka Company Details

11.19.2 Otsuka Business Overview

11.19.3 Otsuka Oncology Drugs Introduction

11.19.4 Otsuka Revenue in Oncology Drugs Business (2021–2026)

11.19.5 Otsuka Recent Development

11.20 Eisai

11.20.1 Eisai Company Details

11.20.2 Eisai Business Overview

11.20.3 Eisai Oncology Drugs Introduction

11.20.4 Eisai Revenue in Oncology Drugs Business (2021–2026)

11.20.5 Eisai Recent Development

11.21 Merck KGaA

11.21.1 Merck KGaA Company Details

11.21.2 Merck KGaA Business Overview

11.21.3 Merck KGaA Oncology Drugs Introduction

11.21.4 Merck KGaA Revenue in Oncology Drugs Business (2021–2026)

11.21.5 Merck KGaA Recent Development

11.22 Gilead Sciences

11.22.1 Gilead Sciences Company Details

11.22.2 Gilead Sciences Business Overview

11.22.3 Gilead Sciences Oncology Drugs Introduction

11.22.4 Gilead Sciences Revenue in Oncology Drugs Business (2021–2026)

11.22.5 Gilead Sciences Recent Development

11.23 Hengrui Medicine

11.23.1 Hengrui Medicine Company Details

11.23.2 Hengrui Medicine Business Overview

11.23.3 Hengrui Medicine Oncology Drugs Introduction

11.23.4 Hengrui Medicine Revenue in Oncology Drugs Business (2021–2026)

11.23.5 Hengrui Medicine Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Roche

Astrazeneca plc

Sanofi

Novartis

Celgene

Bristol–Myers Squibb

Johnson & Johnson

Merck

Pfizer Inc

Amgen Inc

Eli Lilly

AbbVie

Takeda

Astellas

Ipsen S A

Bayer

Biogen Idec

TEVA

Otsuka

Eisai Co Ltd

Merck KGaA

Gilead Sciences

Hengrui Medicine

List of Tables

Table 1. Global Oncology Drugs Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Chemotherapy

Table 3. Key Players of Targeted Therapy

Table 4. Key Players of Immunotherapy (Biologic Therapy)

Table 5. Key Players of Hormonal Therapy

Table 6. Key Players of Others

Table 7. Global Oncology Drugs Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 8. Global Oncology Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 9. Global Oncology Drugs Market Size by Region (US$ Million), 2021–2026

Table 10. Global Oncology Drugs Market Share by Region (2021–2026)

Table 11. Global Oncology Drugs Forecasted Market Size by Region (US$ Million), 2027–2032

Table 12. Global Oncology Drugs Market Share by Region (2027–2032)

Table 13. Oncology Drugs Market Trends

Table 14. Oncology Drugs Market Drivers

Table 15. Oncology Drugs Market Challenges

Table 16. Oncology Drugs Market Restraints

Table 17. Global Oncology Drugs Revenue by Players (US$ Million), 2021–2026

Table 18. Global Oncology Drugs Market Share by Players (2021–2026)

Table 19. Global Top Oncology Drugs Players by Tier (Tier 1, Tier 2, and Tier 3), based on Oncology Drugs Revenue, 2025

Table 20. Ranking of Global Top Oncology Drugs Companies by Revenue (US$ Million) in 2025

Table 21. Global 5 Largest Players Market Share by Oncology Drugs Revenue (CR5 and HHI), 2021–2026

Table 22. Global Key Players of Oncology Drugs, Headquarters and Area Served

Table 23. Global Key Players of Oncology Drugs, Products and Applications

Table 24. Global Key Players of Oncology Drugs, Date of General Availability (GA)

Table 25. Mergers and Acquisitions, Expansion Plans

Table 26. Global Oncology Drugs Market Size by Type (US$ Million), 2021–2026

Table 27. Global Oncology Drugs Revenue Market Share by Type (2021–2026)

Table 28. Global Oncology Drugs Forecasted Market Size by Type (US$ Million), 2027–2032

Table 29. Global Oncology Drugs Revenue Market Share by Type (2027–2032)

Table 30. Global Oncology Drugs Market Size by Application (US$ Million), 2021–2026

Table 31. Global Oncology Drugs Revenue Market Share by Application (2021–2026)

Table 32. Global Oncology Drugs Forecasted Market Size by Application (US$ Million), 2027–2032

Table 33. Global Oncology Drugs Revenue Market Share by Application (2027–2032)

Table 34. North America Oncology Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 35. North America Oncology Drugs Market Size by Country (US$ Million), 2021–2026

Table 36. North America Oncology Drugs Market Size by Country (US$ Million), 2027–2032

Table 37. Europe Oncology Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 38. Europe Oncology Drugs Market Size by Country (US$ Million), 2021–2026

Table 39. Europe Oncology Drugs Market Size by Country (US$ Million), 2027–2032

Table 40. Asia-Pacific Oncology Drugs Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 41. Asia-Pacific Oncology Drugs Market Size by Region (US$ Million), 2021–2026

Table 42. Asia-Pacific Oncology Drugs Market Size by Region (US$ Million), 2027–2032

Table 43. Latin America Oncology Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 44. Latin America Oncology Drugs Market Size by Country (US$ Million), 2021–2026

Table 45. Latin America Oncology Drugs Market Size by Country (US$ Million), 2027–2032

Table 46. Middle East & Africa Oncology Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 47. Middle East & Africa Oncology Drugs Market Size by Country (US$ Million), 2021–2026

Table 48. Middle East & Africa Oncology Drugs Market Size by Country (US$ Million), 2027–2032

Table 49. Roche Company Details

Table 50. Roche Business Overview

Table 51. Roche Oncology Drugs Product

Table 52. Roche Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 53. Roche Recent Development

Table 54. Celgene Company Details

Table 55. Celgene Business Overview

Table 56. Celgene Oncology Drugs Product

Table 57. Celgene Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 58. Celgene Recent Development

Table 59. Novartis Company Details

Table 60. Novartis Business Overview

Table 61. Novartis Oncology Drugs Product

Table 62. Novartis Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 63. Novartis Recent Development

Table 64. Bristol-Myers Squibb Company Details

Table 65. Bristol-Myers Squibb Business Overview

Table 66. Bristol-Myers Squibb Oncology Drugs Product

Table 67. Bristol-Myers Squibb Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 68. Bristol-Myers Squibb Recent Development

Table 69. Johnson & Johnson Company Details

Table 70. Johnson & Johnson Business Overview

Table 71. Johnson & Johnson Oncology Drugs Product

Table 72. Johnson & Johnson Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 73. Johnson & Johnson Recent Development

Table 74. Merck & Co. Company Details

Table 75. Merck & Co. Business Overview

Table 76. Merck & Co. Oncology Drugs Product

Table 77. Merck & Co. Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 78. Merck & Co. Recent Development

Table 79. AstraZeneca Company Details

Table 80. AstraZeneca Business Overview

Table 81. AstraZeneca Oncology Drugs Product

Table 82. AstraZeneca Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 83. AstraZeneca Recent Development

Table 84. Pfizer Company Details

Table 85. Pfizer Business Overview

Table 86. Pfizer Oncology Drugs Product

Table 87. Pfizer Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 88. Pfizer Recent Development

Table 89. Amgen Company Details

Table 90. Amgen Business Overview

Table 91. Amgen Oncology Drugs Product

Table 92. Amgen Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 93. Amgen Recent Development

Table 94. Eli Lilly Company Details

Table 95. Eli Lilly Business Overview

Table 96. Eli Lilly Oncology Drugs Product

Table 97. Eli Lilly Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 98. Eli Lilly Recent Development

Table 99. AbbVie Company Details

Table 100. AbbVie Business Overview

Table 101. AbbVie Oncology Drugs Product

Table 102. AbbVie Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 103. AbbVie Recent Development

Table 104. Takeda Company Details

Table 105. Takeda Business Overview

Table 106. Takeda Oncology Drugs Product

Table 107. Takeda Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 108. Takeda Recent Development

Table 109. Astellas Company Details

Table 110. Astellas Business Overview

Table 111. Astellas Oncology Drugs Product

Table 112. Astellas Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 113. Astellas Recent Development

Table 114. Ipsen Company Details

Table 115. Ipsen Business Overview

Table 116. Ipsen Oncology Drugs Product

Table 117. Ipsen Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 118. Ipsen Recent Development

Table 119. Sanofi Company Details

Table 120. Sanofi Business Overview

Table 121. Sanofi Oncology Drugs Product

Table 122. Sanofi Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 123. Sanofi Recent Development

Table 124. Bayer Company Details

Table 125. Bayer Business Overview

Table 126. Bayer Oncology Drugs Product

Table 127. Bayer Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 128. Bayer Recent Development

Table 129. Biogen Idec Company Details

Table 130. Biogen Idec Business Overview

Table 131. Biogen Idec Oncology Drugs Product

Table 132. Biogen Idec Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 133. Biogen Idec Recent Development

Table 134. Teva Company Details

Table 135. Teva Business Overview

Table 136. Teva Oncology Drugs Product

Table 137. Teva Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 138. Teva Recent Development

Table 139. Otsuka Company Details

Table 140. Otsuka Business Overview

Table 141. Otsuka Oncology Drugs Product

Table 142. Otsuka Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 143. Otsuka Recent Development

Table 144. Eisai Company Details

Table 145. Eisai Business Overview

Table 146. Eisai Oncology Drugs Product

Table 147. Eisai Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 148. Eisai Recent Development

Table 149. Merck KGaA Company Details

Table 150. Merck KGaA Business Overview

Table 151. Merck KGaA Oncology Drugs Product

Table 152. Merck KGaA Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 153. Merck KGaA Recent Development

Table 154. Gilead Sciences Company Details

Table 155. Gilead Sciences Business Overview

Table 156. Gilead Sciences Oncology Drugs Product

Table 157. Gilead Sciences Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 158. Gilead Sciences Recent Development

Table 159. Hengrui Medicine Company Details

Table 160. Hengrui Medicine Business Overview

Table 161. Hengrui Medicine Oncology Drugs Product

Table 162. Hengrui Medicine Revenue in Oncology Drugs Business (US$ Million), 2021–2026

Table 163. Hengrui Medicine Recent Development

Table 164. Research Programs/Design for This Report

Table 165. Key Data Information from Secondary Sources

Table 166. Key Data Information from Primary Sources

Table 167. Authors List of This Report

List of Figures

Figure 1. Oncology Drugs Picture

Figure 2. Global Oncology Drugs Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Oncology Drugs Market Share by Type: 2025 vs 2032

Figure 4. Chemotherapy Features

Figure 5. Targeted Therapy Features

Figure 6. Immunotherapy (Biologic Therapy) Features

Figure 7. Hormonal Therapy Features

Figure 8. Others Features

Figure 9. Global Oncology Drugs Market Size by Application (US$ Million), 2021–2032

Figure 10. Global Oncology Drugs Market Share by Application: 2025 vs 2032

Figure 11. Blood Cancer Case Studies

Figure 12. Breast Cancer Case Studies

Figure 13. Gastrointestinal Cancer Case Studies

Figure 14. Prostate Cancer Case Studies

Figure 15. Respiratory or Lung Cancer Case Studies

Figure 16. Others Case Studies

Figure 17. Oncology Drugs Report Years Considered

Figure 18. Global Oncology Drugs Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 19. Global Oncology Drugs Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 20. Global Oncology Drugs Market Share by Region: 2025 vs 2032

Figure 21. Global Oncology Drugs Market Share by Players in 2025

Figure 22. Global Oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 23. The Top 10 and 5 Players Market Share by Oncology Drugs Revenue in 2025

Figure 24. North America Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. North America Oncology Drugs Market Share by Country (2021–2032)

Figure 26. United States Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. Canada Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. Europe Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Europe Oncology Drugs Market Share by Country (2021–2032)

Figure 30. Germany Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. France Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. U.K. Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Italy Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Russia Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Ireland Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Asia-Pacific Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Asia-Pacific Oncology Drugs Market Share by Region (2021–2032)

Figure 38. China Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Japan Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. South Korea Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Southeast Asia Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. India Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Australia & New Zealand Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Latin America Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Latin America Oncology Drugs Market Share by Country (2021–2032)

Figure 46. Mexico Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Brazil Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Middle East & Africa Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Middle East & Africa Oncology Drugs Market Share by Country (2021–2032)

Figure 50. Israel Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 51. Saudi Arabia Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 52. UAE Oncology Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 53. Roche Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 54. Celgene Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 55. Novartis Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 56. Bristol-Myers Squibb Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 57. Johnson & Johnson Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 58. Merck & Co. Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 59. AstraZeneca Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 60. Pfizer Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 61. Amgen Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 62. Eli Lilly Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 63. AbbVie Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 64. Takeda Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 65. Astellas Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 66. Ipsen Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 67. Sanofi Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 68. Bayer Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 69. Biogen Idec Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 70. Teva Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 71. Otsuka Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 72. Eisai Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 73. Merck KGaA Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 74. Gilead Sciences Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 75. Hengrui Medicine Revenue Growth Rate in Oncology Drugs Business (2021–2026)

Figure 76. Bottom-up and Top-down Approaches for This Report

Figure 77. Data Triangulation

Figure 78. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Oncology Therapeutic Drug Market Research Report 2024

Oncology Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Oncology Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Tumor Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Cell Separation and Characterization in Solid Tumors Market Insights Forecast to 2030

Global Solid Tumor Therapeutics Market Research Report 2024

Global Brain Cancer Targeted Drug Market Research Report 2025

Global Brain Tumor Therapeutics Market Research Report 2024

Global Targeted Therapy for Brain Cancer Market Research Report 2025

Global Solid Tumor Cancer Treatment Market Insights Forecast to 2030

Global Breast Cancer Targeted Drug Market Research Report 2025

Global Rectal Cancer Therapeutics Market Insights Forecast to 2030

Global Oncology Small Molecule Drugs Market Insights Forecast to 2030

Global Tumor Genomics Market Research Report 2024

Global Targeted Therapy for Breast Cancer Market Research Report 2025

Global Prostate Cancer Market Insights Forecast to 2030

Global Breast Cancer Drugs Market Insights Forecast to 2030

Global Brain and Central Nervous System Cancer Treatments Market Research Report 2024

Global Bone Tumor Ablation Devices Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions